Shree Ganesh Remedies Falls to 52-Week Low of Rs.418.6 Amidst Prolonged Downtrend

Recent Price Movement and Market Context

On 8 December 2025, Shree Ganesh Remedies witnessed an intraday low of Rs.418.6, representing a 5.94% decline from its previous close. The stock’s intraday high was Rs.455, which was 2.24% above the previous close, but the downward momentum prevailed by the end of the trading session. This performance underperformed the Pharmaceuticals & Biotechnology sector by 2.4% on the day.

The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a persistent bearish trend. This technical positioning indicates that the stock has not found short-term or long-term support levels to halt the decline.

In comparison, the broader market index, Sensex, opened flat but later declined by 660.51 points, or 0.87%, closing at 84,964.33. Despite this, Sensex remains close to its 52-week high of 86,159.02, trading 1.41% below that peak and maintaining a bullish stance above its 50-day and 200-day moving averages.

Performance Over the Past Year

Over the last twelve months, Shree Ganesh Remedies has recorded a return of -41.95%, significantly lagging behind the Sensex, which posted a positive return of 4.02% during the same period. The stock’s 52-week high was Rs.950, indicating a substantial decline of more than 55% from that peak to the current 52-week low.

This underperformance is notable given the Pharmaceuticals & Biotechnology sector’s relative stability and the broader market’s modest gains. The stock’s trajectory suggests challenges that have weighed on investor sentiment and valuation metrics.

Financial Results and Profitability Trends

Shree Ganesh Remedies has reported negative results for the last three consecutive quarters. The Profit Before Tax (PBT) for the most recent quarter stood at Rs.6.02 crores, reflecting a decline of 28.76% compared to the previous corresponding period. Similarly, the Profit After Tax (PAT) for the latest six months was Rs.8.41 crores, showing a reduction of 23.96% year-on-year.

The company’s Return on Capital Employed (ROCE) for the half-year period is recorded at 16.18%, which is relatively low within the sector. Return on Equity (ROE) stands at 13.3%, indicating moderate profitability relative to shareholders’ equity.

Despite these figures, the company maintains a low Debt to EBITDA ratio of 0.47 times, suggesting a strong capacity to service its debt obligations. This financial metric points to a conservative leverage position amid the current earnings pressures.

Valuation and Market Participation

Shree Ganesh Remedies is trading at a Price to Book Value of 3.7, which is considered fair when compared to its peers’ historical valuations. The stock is currently priced at a discount relative to the average valuations of comparable companies in the Pharmaceuticals & Biotechnology sector.

Notably, domestic mutual funds hold no stake in the company, which may reflect a cautious stance given the recent financial performance and price trends. The absence of significant institutional participation could be indicative of the market’s current assessment of the company’s prospects.

Over the past year, profits have declined by 28.2%, aligning with the downward movement in the stock price. This correlation underscores the challenges faced by the company in maintaining earnings growth amid sectoral and company-specific factors.

Sector and Market Comparison

The Pharmaceuticals & Biotechnology sector has generally shown resilience, with many companies maintaining stable earnings and valuations. In contrast, Shree Ganesh Remedies’ stock has not only underperformed the sector but also the broader BSE500 index, which generated a return of 0.54% over the last year.

This divergence highlights the specific pressures on Shree Ganesh Remedies, which have contributed to its current valuation and price levels. The stock’s fall to Rs.418.6 represents a critical technical level, marking the lowest price point in the past 52 weeks and reflecting the cumulative impact of earnings contraction and market sentiment.

Summary of Key Metrics

To summarise, Shree Ganesh Remedies’ recent performance is characterised by:

• A 52-week low price of Rs.418.6, down from a high of Rs.950 within the year


• Negative returns of 41.95% over the past twelve months


• Declining profits with PBT and PAT falling by 28.76% and 23.96% respectively


• Low Debt to EBITDA ratio of 0.47 times, indicating manageable leverage


• Trading below all major moving averages, signalling sustained downward momentum


• Absence of domestic mutual fund holdings, reflecting limited institutional interest

These factors collectively illustrate the challenges faced by Shree Ganesh Remedies in the current market environment.

Conclusion

Shree Ganesh Remedies’ decline to a 52-week low of Rs.418.6 marks a significant milestone in its recent price trajectory. The stock’s performance over the past year, combined with subdued profitability and valuation metrics, underscores the pressures within the company and its sector. While the broader market and sector indices have maintained relative strength, Shree Ganesh Remedies continues to navigate a difficult phase marked by earnings contraction and subdued investor participation.

Limited Time Only! Upgrade now and get 1 Year of Stock of the week worth Rs. 14,999 for FREE. Don't miss out on this exclusive offer. Claim Your Free Year →